

NIH Public Access

Author Manuscript

Obesity (Silver Spring). Author manuscript; available in PMC 2009 April 24

Published in final edited form as:

Obesity (Silver Spring). 2008 April 1; 16(4): 853-858. doi:10.1038/oby.2008.15.

Visceral Adiposity and Subclinical Coronary Artery Disease in Older Adults: Rancho Bernardo Study

Dong-Jun Kim^{*,†}, Jaclyn Bergstrom^{*}, Elizabeth Barrett-Connor^{*}, and Gail A. Laughlin^{*}

*Department of Family and Preventive Medicine, School of Medicine, University of California, San Diego, La Jolla, California

[†]Department of Internal Medicine, Ilsanpaik Hospital, College of Medicine, Inje University, Koyang, Kyeonggido, South Korea

Abstract

Objective—Despite growing attention to central obesity as a predictor of clinical coronary heart disease (CHD), there are few reports about the association between directly measured visceral obesity and subclinical coronary atherosclerosis in older adults. We examined this association in older community-dwelling adults without clinically recognized CHD.

Research Methods and Procedures—Older adults (190 men, BMI 27.2 \pm 3.6 kg/m²; 220 women, BMI 25.8 \pm 4.6) aged 55 to 88 years (median 69 years) with no history of CHD or coronary revascularization had an electron-beam computed tomography (EBCT) to measure coronary-artery calcification score (CACS), an estimate of coronary-plaque burden. Visceral and subcutaneous adiposity were assessed by a triple-slice EBCT scan at the lumbar 4–5 disc level and height, weight, and waist and hip circumferences were measured.

Results—In sex-specific ordinal logistic regression analyses, no measure of obesity or body fat distribution, including body mass index, waist-hip ratio, waist girth, visceral and subcutaneous fat by EBCT, was significantly associated with CACS before or after adjusting for multiple covariates of CACS (age, smoking, alcohol intake, exercise, pulse pressure, LDL/HDL-cholesterol ratio, and fasting plasma glucose).

Discussion—In older adults without clinically recognized CHD, body weight and fat distribution do not predict coronary artery plaque burden. These results raise questions about the value of weight reduction diets for preventing heart disease in elderly survivors without clinical heart disease.

Keywords

Atherosclerosis; coronary disease; aging; population

INTRODUCTION

Obesity is a powerful risk factor for cardiovascular disease (1–6), predicting coronary heart disease (CHD) independent of other risk factors in long-term follow-up studies (7–9). Growing attention has been paid to particular patterns of fat distribution, especially central (presumably

Conflict of interest: There are no conflicts of interest.

Corresponding Author: Elizabeth Barrett-Connor, MD, Department of Family and Preventive Medicine, School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093-0607, **Telephone**: 858-534-0511 **Fax**: 858-534-8625 **E-mail**: E-mail: ebarrettconnor@ucsd.edu.

visceral) obesity, as a predictor of both clinical coronary events (10) and angiographically documented CHD, independent of body mass index (11,12).

However, most studies of the association between central obesity and CHD have estimated visceral obesity using waist circumference or waist-hip ratio. Directly measured visceral fat mass gives a more precise estimate of visceral obesity. The volume of visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) can be measured directly and simultaneously by electron beam computed tomography (EBCT). Most studies of visceral adiposity and heart disease have been in patients who had clinical coronary events or coronary angiography performed to validate a suspected diagnosis. Body weight and fat distribution could have changed after diagnosis in these patients.

Age influences the pathogenesis of atherosclerosis both by inducing physiological vascular changes and by increasing the duration of exposure to cardiovascular risk factors (13,14). Several studies have shown that the association of CHD risk factors with CHD is attenuated in old age (15–17). The association of visceral obesity with CHD could be different in older adults, especially those without clinical CHD, but there has been no published study about this in a community-dwelling, older, middle to upper-middle class, Caucasian population.

Ultrafast high-intensity EBCT is a noninvasive method to measure coronary artery calcification (CAC), which reflects the amount of coronary artery plaque as assessed by pathology (18) and predicts subsequent cardiac events in both symptomatic and asymptomatic adults (18–19). EBCT can also be used to assess abdominal body fat distribution to the visceral and subcutaneous compartments (20). The objective of the present study was to examine the association of several parameters of obesity, including visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) directly measured by EBCT, with subclinical coronary atherosclerosis, also measured by EBCT, in relatively healthy, older adults who had a low prevalence of hyperglycemia and hypertension and were without clinically manifest CHD.

METHODS

Study Population

Participants were community-dwelling adults from the Rancho Bernardo Study (21), an ongoing population-based study of healthy aging begun in 1972–74 when 82% of adult residents of a middle-class, Caucasian community in southern California were enrolled. Between 1997 and 1999, approximately 70% of surviving local, noninstitutionalized, ambulatory members of this cohort participated in a research evaluation for chronic diseases, when lifestyle, medical history, and CHD risk factor data were ascertained. Between 2001 and 2002, participants who were aged 55 to 88 years and had no history of myocardial infarction, angina pectoris, or coronary artery revascularization were invited to have an EBCT scan for coronary artery calcification. Among eligible participants, 82% joined the EBCT study.

Data Collection and Clinical Evaluation—Participants were evaluated at the UCSD Rancho Bernardo Research Clinic. All gave written informed consent, and the study was approved by the Institutional Review Board of the University of California, San Diego. Structured questionnaires were used to determine demographic characteristics; behaviors including cigarette smoking (current/past/never), alcohol use (\geq 3 alcohol drinks per week), and physical activity (exercise \geq 3 times per week); physician-diagnosed diseases; hospitalizations; and surgeries. Participants who were using prescription or nonprescription medications (in the month before the clinic visit) brought pills and prescriptions to the clinic to be verified and recorded by a nurse.

Two morning blood pressure readings were recorded in seated subjects using a mercury sphygmomanometer and the Hypertension Detection and Follow-up Program protocol (22). Pulse pressure was calculated as the difference between systolic and diastolic pressure.

Plasma glucose was measured by the glucose-oxidase method, and insulin was measured by radioimmunoassay in a diabetes research laboratory. Fasting plasma total cholesterol, HDL cholesterol, and triglyceride levels were measured by enzymatic methods in a Center for Disease Control certified laboratory (23). LDL cholesterol was calculated using the Friedewald formula (24). The LDL/HDL cholesterol ratio was computed as a marker of the atherogenic dyslipidemic state.

Measurement of obesity parameters—Height and weight were measured with participants wearing light-weight clothing without shoes. Body mass index (BMI; kg/m²) was computed as an estimate of obesity. Waist circumference was measured at the bending point (the natural indentation when bending sideways) and the minimum circumference; these measurements correlated by 98%, and the bending-point measurement was used for these analyses. Hip circumference was measured as the largest girth below the waist.

Measurement of CAC score and visceral and subcutaneous fat mass by EBCT —An Imatron C-150 ultrafast CT scanner (Imatron, San Francisco, California) was used to assess CAC and visceral adiposity. Images were obtained with 100-ms scan time in Dr. Michael Wright's LifeScore Clinic in San Diego, California. Approximately 40 to 45 slices were obtained for each subject's heart, using 3-mm slices starting at the level of the carina and proceeding to the level of the diaphragm. Tomographic imaging was electrocardiographically triggered at 40% or 65% of the relative risk interval, depending on the subject's heart rate. CAC was defined as ≥ 2 pixels (area 0.67 mm²) with a density ≥ 130 Hounsfield units. Quantitative calcium scores were calculated using the method of Agatston et al. (25), which is the product of the area of calcification per coronary tomographic segment and a factor rated 1 through 4 based on the calcium X-ray density. The coronary artery calcification score (CACS) was the sum of all coronary artery calcium, and was classified by severity: minimal, 0 to 10; mild, 11 to 100; moderate, 101 to 399; and severe plaque, ≥ 400 . Concurrent with the EBCT scans, a triple 6-mm slice at the lumbar 4–5 disc level was obtained to determine VAT and SAT expressed in cubic centimeters.

Statistical Analysis

Data were analyzed with SPSS (version 11) and SAS (version 9.1). The association of CACS with related variables was evaluated using analysis of variance for continuous variables and chi-square for categorical variables. Fasting glucose and fasting insulin levels had skewed distributions; analyses were performed using log-transformed values. Sex-specific standardized values were used for body size and fat distribution variables as well as all other continuous covariates.

The association of various obesity parameters with CACS was examined by ordinal logistic regression analysis with minimal CACS (0–10) as the reference. Each odds ratio for each parameter of obesity and fat distribution was obtained separately after controlling for age, current smoking, alcohol (3+ drinks per week), regular exercise (3+ times per week), pulse pressure, LDL/HDL cholesterol, and fasting plasma glucose; analyses for women were also adjusted for current estrogen use. Variables used in multivariate analyses were chosen on the basis of known associations in the literature; for consistency the same variables were used in the multivariate models for both sexes. In ordinal logistic regression, the outcome variable is interpreted as a set of cumulative logits based on an increasingly severe CACS, i.e., the odds of greater severity compared to lesser severity; χ^2 tests of the proportional odds assumption

were $P \ge 0.10$ for all ordinal logistic regressions, indicating the proportional odds assumption was met.

Results

There were 410 participants (190 men and 220 women) with no history of heart disease who had measures of CACS, VAT, and SAT by EBCT. Men were older (71.0 ± 8.7 years) on average than women (67.9 ± 7.2 years). The average BMI was 27.2 ± 3.6 kg/m² in men and 25.8 ± 4.6 kg/m² in women; 15.5% of men and 17.7% of women were obese (BMI ≥ 30 kg/m²). Most reported a healthy life style, with current smoking in only 3.6% of men and 5.9% of women, and regular physical activity in 79.8% of men and 73.6% of women. Current use of postmenopausal estrogen was reported by 63% of women.

Men showed higher CACS than women. In sex-specific analyses, divided into four groups according to CACS (minimal, 0 to 10; mild, 11 to 100; moderate, 101 to 399; and severe plaque, ≥ 400), men showed a higher proportion of severe and moderate plaque than women (40% vs. 10% in severe; 18% vs. 12% in moderate) and a lower proportion of minimal and mild plaque than women (18% vs. 50% in minimal; 24% vs. 30% in mild). Table 1 (men) and table 2 (women) show age and age-adjusted coronary heart disease risk factors and body size and composition measures by CACS category. Of these variables, age and current use of blood pressure and lipid medication differed by CACS category in men. In women, age, current use of lipid and diabetes medication, systolic blood pressure, pulse pressure, LDL-cholesterol/HDL-cholesterol, waist girth, and waist-hip ratio increased significantly with increasing CACS, whereas current or past use of estrogen therapy decreased; other variables did not differ.

As shown in Table 3, no parameter of overall or central obesity was significantly associated with CACS in men or women in multivariate ordinal logistic regression models adjusted for age, smoking, alcohol intake, exercise, pulse pressure, LDL/HDL-cholesterol ratio, fasting plasma glucose, and current estrogen therapy (women only). Of these variables, only age was independently associated with CACS in men [5 years increase of age, odds ratio (95% CI), 1.41 (1.17–1.70), p<0.001]; whereas age, pulse pressure, and current estrogen therapy were each independently associated with CACS in women [5 year increase of age, odds ratio (95% CI), 2.03 (1.60–2.56), p<0.001; 1 SD (15.4 mm Hg) increase of pulse pressure, odds ratio (95% CI), 1.61 (1.19–2.19), p=0.002; current estrogen therapy, odds ratio (95% CI), 0.35 (0.19–0.67)]. Additional adjustment for the use of diabetes medications (8 men; 2 women) or lipid-lowering drugs (51 men; 40 women) did not materially alter the results (data not shown).

Discussion

The objective of the present study was to examine the association of obesity including visceral adiposity with subclinical coronary atherosclerosis measured by EBCT-generated CAC score in older adults. As expected, male sex and age were independently associated with CACS, but no parameter of obesity was significantly associated with the degree of coronary artery calcification in men or women before or after adjusting for multiple covariates.

The atherosclerotic process begins with fatty streaks and plaques in young adulthood (26). By the time clinical symptoms appear decades later, the opportunity for primary prevention has been lost (27). In order for primary prevention efforts to be effective, they must focus on risk factors that contribute to the earlier development of disease. Calcification of atherosclerotic plaques begins as early as the second decade of life and continues to progress as the plaque matures (28). Others have reported that age and sex are the strongest clinical correlates of CAC (29–32), compatible with results shown here. After controlling for body size and other

cardiovascular risk factors, men in this cohort had a nearly five-fold increased prevalence of moderate to severe coronary artery plaque burden compared to women.

We did not observe a significant association of CACS with any obesity parameter. In contrast, Snell-Bergeon (33) reported that BMI, waist circumference, and visceral fat by CT were significantly associated with CACS in 383 men and 379 women; VAT was not superior to BMI or waist circumference. This cohort was much younger (aged 20–58 years) than the Rancho Bernardo cohort (aged 55 to 88). In the large Rotterdam Coronary Calcification Study, older adults with or without a history of CHD had less favorable CHD risk factors than our study, and CACS was associated with body mass index. The median values of CACS in the Rotterdam study were higher than those in Rancho Bernardo [men, median(interquartile range), 312(62–969) in the Rotterdam study *vs*. 201(41–720) in our study; women, 56(5–261) *vs*. 13(0–119)] (34). In a study of 443 asymptomatic younger adults (aged 20–58 years), waist circumference, waist-hip ratio, and BMI were positively related to 9-year progression of CAC only in those at relatively low risk of CHD (10-year risk <10% by the Framingham risk equation) (35). These studies suggest that the association between CAC score and overall, central, and visceral obesity may differ in younger versus older populations.

The association of obesity with CAC score may be more difficult to identify in older persons, against a ground of lifetime exposure to cardiovascular risk factors. Newman and colleagues reported that the extent of CAC was strongly associated with age through the ninth decade, but risk factor levels were only weakly associated with CACS after age 65 years, concordant with our results (36). This and other studies show that the association of risk factors with CHD is attenuated in old age (15–17). Stevens and colleagues reported that greater body weight increased the 12-year risk of death from cardiovascular disease, but the relative risk was lowest among older persons (14). Taken together, these studies support the hypothesis that the risk factors associated with obesity may have worked their spell years before, that is, that weight and fat distribution measures are more important at younger ages, and that high-risk individuals have clinical CHD by age 65. Alternatively, weight loss in older adults may have obscured an obesity-CHD association.

The Rancho Bernardo Study cohort was older, middle to upper-middle class, Caucasian, and had a healthy life style and access to health care. Almost all saw a physician at least once a year. Most importantly, all those with a history of coronary artery disease were excluded from the EBCT test because the goal of our EBCT study was to examine the association between obesity and subclinical coronary atherosclerosis. This design may have lessened the statistical power to show obesity-CAC score associations because individuals with clinically manifest coronary heart disease were excluded. Further, all studies of the elderly are subject to survivor bias. However, there was wide range of CAC scores (58% of men and 21% of women had severe or moderate plaque), and about 15% were obese individuals by the BMI criteria of \geq 30 kg/m².

This is a cross-sectional study, and therefore cannot establish causality. It seems unlikely, however, that absence of subclinical heart disease caused a more favorable weight, waist or VAT pattern. Despite the limitations of survival bias and cross-sectional design, this study is concordant with other reports showing clinically measured obesity is not a strong risk factor for coronary atherosclerosis in older adults.

In conclusion, neither overall obesity nor directly measured visceral obesity significantly predicted atherosclerosis in older survivors without clinical heart disease. The importance of weight control to prevent coronary heart disease in healthy elderly survivors is uncertain.

Obesity (Silver Spring). Author manuscript; available in PMC 2009 April 24.

ABBREVIATIONS AND ACRONYMS

CACS, coronary artery calcification scores; CHD, coronary heart disease; EBCT, electron beam computed tomography; HDL cholesterol, high-density lipoprotein cholesterol; LDL cholesterol, low-density lipoprotein cholesterol; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue.

Acknowledgment

This research was supported by the National Institute of Aging Grant NIA 5R01 AG07181 and the National Institute of Diabetes and Digestive and Kidney Diseases Grant NIDDK 5R01 DKK31801.

References

- Kannel WB, Cupples LA, Ramaswami R, Stokes J III, Kreger BE, Higgins M. Regional obesity and risk of cardiovascular disease; the Framingham Study. J Clin Epidemiol 1991;44:183–190. [PubMed: 1995775]
- Rexrode KM, Carey VJ, Hennekens CH, et al. Abdominal adiposity and coronary heart disease in women. JAMA 1998;280:1843–1848. [PubMed: 9846779]
- Rexrode KM, Buring JE, Manson JE. Abdominal and total adiposity and risk of coronary heart disease in men. Int J Obes Relat Metab Disord 2001;25:1047–1056. [PubMed: 11443505]
- Rimm EB, Stampfer MJ, Giovannucci E, et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol 1995;141:1117–1127. [PubMed: 7771450]
- Krauss RM, Winston M, Fletcher BJ, Grundy SM. Obesity: impact on cardiovascular disease. Circulation 1998;98:1472–1476.
- Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999;282:1523–1529. [PubMed: 10546691]
- Dey DK, Lissner L. Obesity in 70-year-old subjects as risk factor for 15-year coronary heart disease incidence. Obes Res 2003;11:817–827. [PubMed: 12855750]
- Jonsson S, Hedblad B, Engstrom G, Nilsson P, Berglund G, Janzon L. Influence of obesity on cardiovascular risk. Twenty-three year follow-up of 22,025 men from an urban Swedish population. Int J Obes Relat Metab Disord 2002;26:1046–1053. [PubMed: 12119569]
- Kim KS, Owen WL, Williams D, Adams-Campell LL. A comparison between BMI and Conicity index on predicting coronary heart disease: the Framingham Heart Study. Ann Epidemiol 2000;10:424–431. [PubMed: 11018345]
- Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. BMJ 1984;289:1257–1261. [PubMed: 6437507]
- Kortelainen ML, Sarkioja T. Coronary atherosclerosis associated with body structure and obesity in 599 women aged between 15 and 50 years. Int J Obes Relat Metab Disord 1999;23:838–844. [PubMed: 10490785]
- Hauner H, Stangl K, Schmatz C, Burger K, Blomer H, Pfeiffer EF. Body fat distribution in men with angiographically confirmed coronary artery disease. Atherosclerosis 1990;85:203–210. [PubMed: 2102084]
- Wilson PW, Hoeg JM, D'Agostino RB, et al. Cumulative effects of high cholesterol levels, high blood pressure and cigarette smoking on carotid stenosis. New Engl J Med 1997;337:516–522. [PubMed: 9262494]
- Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL. The effect of age on the association between body-mass index and mortality. New Engl J Med 1998;338:1–7. [PubMed: 9414324]
- Newman AB, Shemanski L, Manolio TA, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1999;19:538–545. [PubMed: 10073955]

Obesity (Silver Spring). Author manuscript; available in PMC 2009 April 24.

- 16. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823–2828. [PubMed: 3773199]
- Frost PH, Davis BR, Burlando AJ, et al. Coronary heart disease risk factors in men and women aged 60 and older: findings from the Systolic Hypertension in the Elderly Program. Circulation 1996;94:26–34. [PubMed: 8964114]
- Wexler L, Brundage B, Crouse J, et al. for the Writing Group. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications: a statement for health professionals from the American Heart Association. Circulation 1996;94:1175–1192. [PubMed: 8790070]
- Taylor AJ, Bindeman J, Feuerstein I, Cao F, Brazaitis M, O'Malley PG. Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project. J Am Coll Cardiol 2005;6:46:807–814. [PubMed: 16139129]
- 20. Plourde G. The role of radiologic methods in assessing body composition and related metabolic parameters. Nutr. Rev 1997;55(8):289–296. [PubMed: 9287478]
- 21. Barrett-Connor E. The prevalence of diabetes mellitus in an adult community as determined by history or fasting hyperglycemia. Am J Epidemiol 1980;111:705–712. [PubMed: 7386445]
- 22. Hypertension Detection and Follow-Up Program Cooperative Group. The Hypertension Detection and Follow-Up Program. Prev Med 1976;5:207–215. [PubMed: 935073]
- 23. Lipid Research Clinics Program Manual of Laboratory Operations: Vol 1: Lipid and Lipoprotein Analysis. Vol. 2nd ed.. Washington, DC: US Government Printing Office, US Dept of Health, Education, and Welfare; 1974. NIH publication No. 75–628
- Freidewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502. [PubMed: 4337382]
- Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827–832. [PubMed: 2407762]
- 26. Strong JP, Malcom GT, McMahan CA, et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathological Determinants of Atherosclerosis in Youth Study. JAMA 1999;281:727–735. [PubMed: 10052443]
- Adams MR, Celermajer DS. Detection of presymptomatic atherosclerosis: a current perspective. Clin Sci (Lond) 1999;97:615–624. [PubMed: 10545314]
- Stary HC. The development of calcium deposits in atherosclerotic lesions and their persistence after lipid regression. Am J Cardiol 2001;88:16E–19E.
- Allison MA, Wright CM. Age and gender are the strongest clinical correlates of prevalent coronary calcification. Int J Cardiol 2005;98:325–330. [PubMed: 15686786]
- Raggi P, Cooil B, Hadi A, Friede G. Predictors of aortic and coronary artery calcium on a screening electron beam tomographic scan. Am J Cardiol 2003;91:744–746. [PubMed: 12633815]
- Hoff JA, Daviglus ML, Chomka EV, Krainik AJ, Sevrukov A, Kondos GT. Conventional coronary artery disease risk factors and coronary artery calcium detected by electron beam tomography in 30,908 healthy individuals. Ann Epidemiol 2003;13:163–169. [PubMed: 12604159]
- Feuerstein IM, Brazaitis MP, Zoltick JM, et al. Electron beam computed tomography screening of the coronary arteries: experience with 3263 patients at Walter Reed Army Medical Center. Mil Med 2001;166:432–442. [PubMed: 11370209]
- Snell-Bergeon JK, Hokanson JE, Kinney GL, et al. Measurement of abdominal fat by CT compared to waist circumference and BMI in explaining the presence of coronary calcium. Int J Obes Relat Metab Disord 2004;28:1594–1599. [PubMed: 15467773]
- Oei H-HS, Vliegenthart R, Hofman A, Oudkerk M, Witteman JCM. Risk factors for coronary calcification in older subjects: The Rotterdam Coronary Calcification Study. Eur Heart J 2004;25:48– 55. [PubMed: 14683742]

Obesity (Silver Spring). Author manuscript; available in PMC 2009 April 24.

- Cassidy AE, Bielak LF, Zhou Y, et al. Progression of subclinical coronary atherosclerosis: does obesity make a difference? Circulation 2005;111:1877–1882. [PubMed: 15837939]
- Newman AB, Naydeck BL, Sutton-Tyrrell K, Feldman A, Edmundowicz D, Kuller LH. Coronary artery calcification in older adults to age 99: prevalence and risk factors. Circulation 2001;104:2679– 2684. [PubMed: 11723018]

Age and Age-adjusted Characteristics of Men (n=190) according to CAC score

	CACS			
	0–10 (n=33)	11–100 (n=32)	101–399 (n=48)	≥400 (n=77)
Age (years) *	67.7 ± 1.5	68.9 ± 1.7	69.9 ± 1.2	74.8 ± 0.7
Past or current smoking (%)	42.2 ± 8.8	53.0 ± 8.9	54.1 ± 7.2	62.6 ± 5.9
Exercise \geq 3 times / week (%)	73.7 ± 6.9	84.2 ± 5.9	76.2 ± 6.7	81.8 ± 4.6
Alcohol \geq 3 times / week (%)	62.1 ± 8.6	54.1 ± 8.6	58.9 ± 7.0	70.0 ± 5.7
Anti-hypertensive medication $(\%)^{\ddagger}$	15.5 ± 8.0	27.3 ± 8.1	36.8 ± 6.6	35.7 ± 5.4
Anti-lipid medication $(\%)^{\dagger}$	12.7 ± 8.0	20.9 ± 8.0	24.0 ± 6.4	37.6 ± 5.2
Anti-diabetes medication (%)	1.9 ± 3.6	2.3 ± 3.6	5.8 ± 2.9	5.1 ± 2.4
Body mass index (kg/m ²)	26.6 ± 0.6	27.0 ± 0.6	27.1 ± 0.5	27.5 ± 0.4
Waist circumference (cm)	94.5 ± 1.8	96.0 ± 1.8	95.6 ± 1.5	97.5 ± 1.2
Waist-hip ratio	0.92 ± 0.01	0.93 ± 0.01	0.93 ± 0.01	0.94 ± 0.01
Fat compartments by EBCT	(n=32)	(n=30)	(n=47)	(n=76)
Visceral fat (cm ³)	84.9 ± 12.0	104.9 ± 12.2	90.9 ± 9.8	97.0 ± 7.9
Subcutaneous fat (cm ³)	116.2 ± 14.3	145.0 ± 14.5	117.5 ± 11.6	130.1 ± 9.4
Visceral fat / subcutaneous fat	0.74 ± 0.06	0.76 ± 0.06	0.83 ± 0.05	0.80 ± 0.04
Systolic blood pressure (mmHg)	128.8 ± 3.3	130.0 ± 3.3	133.2 ± 2.7	133.1 ± 2.2
Diastolic blood pressure (mmHg)	78.0 ± 1.4	78.7 ± 1.4	78.1 ± 1.2	77.4 ± 0.9
Pulse pressure (mmHg)	50.8 ± 2.6	51.3 ± 2.6	55.1 ± 2.1	55.7 ± 1.7
LDL cholesterol (mg/dl)	116.6 ± 5.2	122.1 ± 5.2	113.7 ± 4.3	127.3 ± 3.5
HDL cholesterol (mg/dl)	48.9 ± 2.1	49.6 ± 2.1	48.2 ± 1.7	51.6 ± 1.4
LDL / HDL cholesterol	2.47 ± 0.13	2.57 ± 0.13	2.43 ± 0.11	2.59 ± 0.09
Fasting glucose (mmol/l)	5.74 ± 0.17	5.78 ± 0.18	6.04 ± 0.14	6.02 ± 0.12
Fasting insulin (pmol/l)	123.5 ± 14.4	123.3 ± 14.4	157.2 ± 11.7	143.2 ± 9.6

Data are mean \pm SEM or %.

EBCT, electron beam computed tomography.

Fasting glucose and fasting insulin were log-transformed.

p for trend < 0.001

 $f_{p < 0.01}$

≠ p < 0.05.

Age and Age-adjusted Characteristics of women (n=220) according to CAC score

$\begin{tabular}{ c c c c c c } \hline 0 & -10 & 11-100 & 101-399 & (n=41) \\ \hline (n=108) & 11-100 & (n=50) & (n=41) \\ \hline (n=50) & (n=50) & (n=50) & (n=41) \\ \hline (n=108) & 49.7 \pm 5.2 & 44.2 \pm 7.2 & 56.5 \pm 8.2 \\ \hline Exercise \ge 3 times / week (\%) & 49.7 \pm 5.2 & 44.2 \pm 7.2 & 56.5 \pm 8.2 \\ \hline Exercise \ge 3 times / week (\%) & 75.2 \pm 4.5 & 72.0 \pm 6.3 & 79.0 \pm 7.2 \\ \hline Alcohol \ge 3 times / week (\%) & 48.7 \pm 5.1 & 55.8 \pm 7.1 & 32.2 \pm 8.1 \\ \hline Anti-hypertensive medication (\%) & 23.8 \pm 4.5 & 34.3 \pm 6.3 & 23.6 \pm 7.2 \\ \hline Anti-lipid medication (\%)^{\vec{T}} & 0.1 \pm 2 & 0.4 \pm 1.6 & 5.7 \pm 1.9 \\ \hline Current/past estrogen therapy (\%)^{\vec{T}} & 72.2 \pm 4.8 & 55.9 \pm 6.7 & 54.9 \pm 7.7 \\ \hline Body mass index (kg/m2) & 25.5 \pm 0.5 & 25.6 \pm 0.7 & 26.5 \pm 0.8 \\ \hline Waist circumference (cm)^{\vec{T}} & 0.77 \pm 0.01 & 0.77 \pm 0.01 & 0.80 \pm 0.0 \\ \hline Fat compartments by EBCT & (n=104) & (n=49) & (n=40) \\ \hline Visceral fat (cm3) & 59.2 \pm 3.6 & 63.2 \pm 4.9 & 67.2 \pm 5.6 \\ Subcutaneous fat & 0.41 \pm 0.02 & 0.48 \pm 0.03 & 0.44 \pm 0.03 \\ \hline Systolic blood pressure (mmHg)^{\vec{T}} & 51.8 \pm 1.4 & 53.5 \pm 2.0 & 54.8 \pm 1.3 \\ \hline Diastolic blood pressure (mmHg)^{\vec{T}} & 51.8 \pm 1.4 & 53.5 \pm 2.0 & 54.8 \pm 2.3 \\ \hline LDL cholesterol (mg/dl) & 121.7 \pm 3.1 & 122.4 \pm 4.3 & 121.1 \pm 4.5 \\ \hline HDL cholesterol (mg/dl) & 69.0 \pm 1.7 & 68.3 \pm 2.4 & 58.7 \pm 2.7 \\ \hline LDL / HDL cholesterol \vec{T} & 1.89 \pm 0.08 & 1.96 \pm 0.11 & 2.16 \pm 0.15 \\ \hline $		ACS			
Age (years)64.5 \pm 0.670.1 \pm 1.072.3 \pm 0.9Past or current smoking (%)49.7 \pm 5.244.2 \pm 7.256.5 \pm 8.2Exercise \geq 3 times / week (%)75.2 \pm 4.572.0 \pm 6.379.0 \pm 7.2Alcohol \geq 3 times / week (%)48.7 \pm 5.155.8 \pm 7.132.2 \pm 8.1Anti-hypertensive medication (%)23.8 \pm 4.534.3 \pm 6.323.6 \pm 7.2Anti-dipid medication (%)23.8 \pm 4.534.3 \pm 6.323.6 \pm 7.2Anti-dipid medication (%)23.8 \pm 4.534.3 \pm 6.323.6 \pm 7.2Anti-dipid medication (%)72.2 \pm 4.855.9 \pm 6.754.9 \pm 7.7Body mass index (kg/m ²)25.5 \pm 0.525.6 \pm 0.726.5 \pm 0.8Waist circumference (cm) \ddagger 78.8 \pm 1.280.0 \pm 1.783.8 \pm 1.9Waist-hip ratio \ddagger 0.77 \pm 0.010.77 \pm 0.010.80 \pm 0.0Fat compartments by EBCT(n=104)(n=49)(n=40)Visceral fat (cm3)59.2 \pm 3.663.2 \pm 4.967.2 \pm 5.6Subcutaneous fat (cm3)155.4 \pm 7.5141.1 \pm 10.3167.8 \pm 11.1Visceral fat / subcutaneous fat0.41 \pm 0.020.48 \pm 0.030.44 \pm 0.02Systolic blood pressure (mmHg) \ddagger 74.9 \pm 0.876.7 \pm 1.173.0 \pm 1.3Pulse pressure (mmHg) \ddagger 51.8 \pm 1.453.5 \pm 2.054.8 \pm 2.3LDL cholesterol (mg/dl)69.0 \pm 1.768.3 \pm 2.458.7 \pm 2.7LDL / HDL cholesterol (\ddagger 1.89 \pm 0.081.96 \pm 0.112.16 \pm 0.12	≥400 (n=21)	101-399 (n=41)	11–100 (n=50)	0–10 (n=108)	
Past or current smoking (%) 49.7 ± 5.2 44.2 ± 7.2 56.5 ± 8.2 Exercise ≥ 3 times / week (%) 75.2 ± 4.5 72.0 ± 6.3 79.0 ± 7.2 Alcohol ≥ 3 times / week (%) 48.7 ± 5.1 55.8 ± 7.1 32.2 ± 8.1 Anti-hypertensive medication (%) 23.8 ± 4.5 34.3 ± 6.3 23.6 ± 7.2 Anti-lipid medication (%) p^{\ddagger} 11.2 ± 4.0 22.6 ± 5.5 32.8 ± 6.3 Anti-diabetes medication (%) p^{\ddagger} 0.0 ± 1.2 0.4 ± 1.6 5.7 ± 1.9 Current/past estrogen therapy (%) p^{\ddagger} 72.2 ± 4.8 55.9 ± 6.7 54.9 ± 7.7 Body mass index (kg/m ²) 25.5 ± 0.5 25.6 ± 0.7 26.5 ± 0.8 Waist circumference (cm) p^{\ddagger} 78.8 ± 1.2 80.0 ± 1.7 83.8 ± 1.9 Waist-hip ratio p^{\ddagger} 0.77 ± 0.01 0.77 ± 0.01 0.80 ± 0.0 Fat compartments by EBCT(n=104)(n=49)(n=40)Visceral fat (cm3) 59.2 ± 3.6 63.2 ± 4.9 67.2 ± 5.6 Subcutaneous fat (cm3) 155.4 ± 7.5 141.1 ± 10.3 167.8 ± 11.4 Visceral fat / subcutaneous fat 0.41 ± 0.02 0.48 ± 0.03 0.44 ± 0.03 Systolic blood pressure (mmHg) 74.9 ± 0.8 76.7 ± 1.1 73.0 ± 1.3 Pulse pressure (mmHg) 74.9 ± 0.8 76.7 ± 1.1 73.0 ± 1.3 Pulse pressure (mmHg) 74.9 ± 0.8 76.7 ± 1.1 73.0 ± 1.3 Pulse pressure (mmHg) 74.9 ± 0.8 76.7 ± 1.1 73.0 ± 1.3 Pulse pressure (mmHg) 74.9 ± 0.8 76.7 ± 1.1 73.0 ± 1.3 <td>71.1 ± 1.4</td> <td>72.3 ± 0.9</td> <td>70.1 ± 1.0</td> <td>64.5 ± 0.6</td> <td>Age (years)*</td>	71.1 ± 1.4	72.3 ± 0.9	70.1 ± 1.0	64.5 ± 0.6	Age (years)*
Exercise ≥ 3 times / week (%) 75.2 ± 4.5 72.0 ± 6.3 79.0 ± 7.2 Alcohol ≥ 3 times / week (%) 48.7 ± 5.1 55.8 ± 7.1 32.2 ± 8.1 Anti-hypertensive medication (%) 23.8 ± 4.5 34.3 ± 6.3 23.6 ± 7.2 Anti-lipid medication (%) ^{t^{\dagger}} 11.2 ± 4.0 22.6 ± 5.5 32.8 ± 6.3 Anti-diabetes medication (%) ^{t^{\dagger}} 0.0 ± 1.2 0.4 ± 1.6 5.7 ± 1.9 Current/past estrogen therapy (%) ^{t^{\dagger}} 72.2 ± 4.8 55.9 ± 6.7 54.9 ± 7.7 Body mass index (kg/m ²) 25.5 ± 0.5 25.6 ± 0.7 26.5 ± 0.8 Waist circumference (cm) ^{t^{\dagger}} 0.77 ± 0.01 0.77 ± 0.01 0.80 ± 0.0 Fat compartments by EBCT(n=104)(n=49)(n=40)Visceral fat (cm3) 59.2 ± 3.6 63.2 ± 4.9 $67.2 \pm 5.6 \pm 0.7$ Subcutaneous fat 0.41 ± 0.02 0.48 ± 0.03 0.44 ± 0.03 Visceral fat (cm3) 155.4 ± 7.5 141.1 ± 10.3 167.8 ± 11.7 Visceral fat (cm3) 74.9 ± 0.8 76.7 ± 1.1 73.0 ± 1.3 Diastolic blood pressure (mmHg) ^{t^{\dagger}} 51.8 ± 1.4 53.5 ± 2.0 54.8 ± 2.3 LDL cholesterol (mg/dl) 69.0 ± 1.7 68.3 ± 2.4 58.7 ± 2.7 LDL / HDL cholesterol t^{t} 1.89 ± 0.08 1.96 ± 0.11 2.16 ± 0.11	57.4 ± 11.1	56.5 ± 8.2	44.2 ± 7.2	49.7 ± 5.2	Past or current smoking (%)
Alcohol ≥ 3 times / week (%) 48.7 ± 5.1 55.8 ± 7.1 32.2 ± 8.1 Anti-hypertensive medication (%) 23.8 ± 4.5 34.3 ± 6.3 23.6 ± 7.2 Anti-lipid medication (%) t^{\dagger} 11.2 ± 4.0 22.6 ± 5.5 32.8 ± 6.3 Anti-diabetes medication (%) t^{\dagger} 0.0 ± 1.2 0.4 ± 1.6 5.7 ± 1.9 Current/past estrogen therapy (%) t^{\dagger} 72.2 ± 4.8 55.9 ± 6.7 54.9 ± 7.7 Body mass index (kg/m ²) 25.5 ± 0.5 25.6 ± 0.7 26.5 ± 0.8 Waist circumference (cm) t^{\ddagger} 78.8 ± 1.2 80.0 ± 1.7 83.8 ± 1.9 Waist-hip ratio t^{\ddagger} 0.77 ± 0.01 0.77 ± 0.01 0.80 ± 0.0 Fat compartments by EBCT(n=104)(n=49)(n=40)Visceral fat (cm3) 59.2 ± 3.6 63.2 ± 4.9 67.2 ± 5.6 Subcutaneous fat (cm3) 155.4 ± 7.5 141.1 ± 10.3 167.8 ± 11.4 Visceral fat / subcutaneous fat 0.41 ± 0.02 0.48 ± 0.03 0.44 ± 0.03 Systolic blood pressure (mmHg) 74.9 ± 0.8 76.7 ± 1.1 73.0 ± 1.3 Pulse pressure (mmHg) t^{\dagger} 51.8 ± 1.4 53.5 ± 2.0 54.8 ± 2.3 LDL cholesterol (mg/dl) 121.7 ± 3.1 122.4 ± 4.3 121.1 ± 4.5 HDL cholesterol (mg/dl) 69.0 ± 1.7 68.3 ± 2.4 58.7 ± 2.7 LDL / HDL cholesterol t^{\ddagger} 1.89 ± 0.08 1.96 ± 0.11 2.16 ± 0.11	59.1 ± 9.7	79.0 ± 7.2	72.0 ± 6.3	75.2 ± 4.5	Exercise \geq 3 times / week (%)
Anti-hypertensive medication (%) 23.8 ± 4.5 34.3 ± 6.3 23.6 ± 7.2 Anti-lipid medication (%) j^{\ddagger} 11.2 ± 4.0 22.6 ± 5.5 32.8 ± 6.3 Anti-diabetes medication (%) j^{\ddagger} 0.0 ± 1.2 0.4 ± 1.6 5.7 ± 1.9 Current/past estrogen therapy (%) j^{\ddagger} 72.2 ± 4.8 55.9 ± 6.7 54.9 ± 7.7 Body mass index (kg/m ²) 25.5 ± 0.5 25.6 ± 0.7 26.5 ± 0.8 Waist circumference (cm) j^{\ddagger} 78.8 ± 1.2 80.0 ± 1.7 83.8 ± 1.9 Waist-hip ratio j^{\ddagger} 0.77 ± 0.01 0.77 ± 0.01 0.80 ± 0.00 Fat compartments by EBCT(n=104)(n=49)(n=40)Visceral fat (cm3) 59.2 ± 3.6 63.2 ± 4.9 67.2 ± 5.6 Subcutaneous fat (cm3) 155.4 ± 7.5 141.1 ± 10.3 167.8 ± 11.1 Visceral fat / subcutaneous fat 0.41 ± 0.02 0.48 ± 0.03 0.44 ± 0.03 Systolic blood pressure (mmHg) j^{\ddagger} 51.8 ± 1.4 53.5 ± 2.0 54.8 ± 2.3 LDL cholesterol (mg/dl) 121.7 ± 3.1 122.4 ± 4.3 121.1 ± 4.5 HDL cholesterol j^{\ddagger} 1.89 ± 0.08 1.96 ± 0.11 2.16 ± 0.11	58.7 ± 10.9	32.2 ± 8.1	55.8 ± 7.1	48.7 ± 5.1	Alcohol \geq 3 times / week (%)
Anti-lipid medication $(\%)^{\vec{t}}$ 11.2 ± 4.0 22.6 ± 5.5 32.8 ± 6.3 Anti-diabetes medication $(\%)^{\vec{t}}$ 0.0 ± 1.2 0.4 ± 1.6 5.7 ± 1.9 Current/past estrogen therapy $(\%)^{\vec{t}}$ 72.2 ± 4.8 55.9 ± 6.7 54.9 ± 7.7 Body mass index (kg/m^2) 25.5 ± 0.5 25.6 ± 0.7 26.5 ± 0.8 Waist circumference $(cm)^{\vec{t}}$ 78.8 ± 1.2 80.0 ± 1.7 83.8 ± 1.9 Waist-hip ratio $^{\vec{t}}$ 0.77 ± 0.01 0.77 ± 0.01 0.80 ± 0.00 Fat compartments by EBCT $(n=104)$ $(n=49)$ $(n=40)$ Visceral fat (cm3) 59.2 ± 3.6 63.2 ± 4.9 67.2 ± 5.6 Subcutaneous fat (cm3) 155.4 ± 7.5 141.1 ± 10.3 167.8 ± 11.2 Visceral fat / subcutaneous fat 0.41 ± 0.02 0.48 ± 0.03 0.44 ± 0.03 Systolic blood pressure (mmHg) $^{\vec{t}}$ 126.7 ± 1.9 130.2 ± 2.6 127.8 ± 3.0 Diastolic blood pressure (mmHg) $^{\vec{t}}$ 51.8 ± 1.4 53.5 ± 2.0 54.8 ± 2.3 LDL cholesterol (mg/dl) 121.7 ± 3.1 122.4 ± 4.3 121.1 ± 4.5 HDL cholesterol (mg/dl) 69.0 ± 1.7 68.3 ± 2.4 58.7 ± 2.7 LDL / HDL cholesterol $^{\vec{t}}$ 1.89 ± 0.08 1.96 ± 0.11 2.16 ± 0.11	30.9 ± 9.7	23.6 ± 7.2	34.3 ± 6.3	23.8 ± 4.5	Anti-hypertensive medication (%)
Anti-diabetes medication $(\%)^{\dagger}$ 0.0 ± 1.2 0.4 ± 1.6 5.7 ± 1.9 Current/past estrogen therapy $(\%)^{\dagger}$ 72.2 ± 4.8 55.9 ± 6.7 54.9 ± 7.7 Body mass index (kg/m^2) 25.5 ± 0.5 25.6 ± 0.7 26.5 ± 0.8 Waist circumference $(cm)^{\dagger}$ 78.8 ± 1.2 80.0 ± 1.7 83.8 ± 1.9 Waist-hip ratio ‡ 0.77 ± 0.01 0.77 ± 0.01 0.80 ± 0.00 Fat compartments by EBCT $(n=104)$ $(n=49)$ $(n=40)$ Visceral fat (cm3) 59.2 ± 3.6 63.2 ± 4.9 67.2 ± 5.6 Subcutaneous fat (cm3) 155.4 ± 7.5 141.1 ± 10.3 167.8 ± 11.4 Visceral fat / subcutaneous fat 0.41 ± 0.02 0.48 ± 0.03 0.44 ± 0.03 Systolic blood pressure (mmHg) ‡ 126.7 ± 1.9 130.2 ± 2.6 127.8 ± 3.6 Diastolic blood pressure (mmHg) 74.9 ± 0.8 76.7 ± 1.1 73.0 ± 1.3 Pulse pressure (mmHg) ‡ 51.8 ± 1.4 53.5 ± 2.0 54.8 ± 2.3 LDL cholesterol (mg/dl) 121.7 ± 3.1 122.4 ± 4.3 121.1 ± 4.9 HDL cholesterol $\frac{1}{7}$ 1.89 ± 0.08 1.96 ± 0.11 2.16 ± 0.11	19.9 ± 8.5	32.8 ± 6.3	22.6 ± 5.5	11.2 ± 4.0	Anti-lipid medication $(\%)^{\ddagger}$
Current/past estrogen therapy $(\%)^{\dagger}$ 72.2 ± 4.8 55.9 ± 6.7 54.9 ± 7.7 Body mass index (kg/m^2) 25.5 ± 0.5 25.6 ± 0.7 26.5 ± 0.8 Waist circumference $(cm)^{\frac{1}{7}}$ 78.8 ± 1.2 80.0 ± 1.7 83.8 ± 1.9 Waist-hip ratio $^{\frac{1}{7}}$ 0.77 ± 0.01 0.77 ± 0.01 0.80 ± 0.0 Fat compartments by EBCT $(n=104)$ $(n=49)$ $(n=40)$ Visceral fat (cm3) 59.2 ± 3.6 63.2 ± 4.9 67.2 ± 5.6 Subcutaneous fat (cm3) 155.4 ± 7.5 141.1 ± 10.3 167.8 ± 11.1 Visceral fat / subcutaneous fat 0.41 ± 0.02 0.48 ± 0.03 0.44 ± 0.02 Systolic blood pressure (mmHg) $^{\frac{1}{7}}$ 126.7 ± 1.9 130.2 ± 2.6 127.8 ± 3.0 Diastolic blood pressure (mmHg) † 51.8 ± 1.4 53.5 ± 2.0 54.8 ± 2.3 LDL cholesterol (mg/dl) 121.7 ± 3.1 122.4 ± 4.3 121.1 ± 4.9 HDL cholesterol (mg/dl) 69.0 ± 1.7 68.3 ± 2.4 58.7 ± 2.7 LDL / HDL cholesterol $^{\frac{1}{7}}$ 1.89 ± 0.08 1.96 ± 0.11 2.16 ± 0.11	5.4 ± 2.5	5.7 ± 1.9	0.4 ± 1.6	0.0 ± 1.2	Anti-diabetes medication $(\%)^{\dagger}$
Body mass index (kg/m²) 25.5 ± 0.5 25.6 ± 0.7 26.5 ± 0.8 Waist circumference (cm) $\frac{1}{7}$ 78.8 ± 1.2 80.0 ± 1.7 83.8 ± 1.9 Waist-hip ratio $\frac{1}{7}$ 0.77 ± 0.01 0.77 ± 0.01 0.80 ± 0.0 Fat compartments by EBCT(n=104)(n=49)(n=40)Visceral fat (cm3) 59.2 ± 3.6 63.2 ± 4.9 67.2 ± 5.6 Subcutaneous fat (cm3) 155.4 ± 7.5 141.1 ± 10.3 167.8 ± 11.2 Visceral fat / subcutaneous fat 0.41 ± 0.02 0.48 ± 0.03 0.44 ± 0.03 Systolic blood pressure (mmHg) $\frac{1}{7}$ 126.7 ± 1.9 130.2 ± 2.6 127.8 ± 3.6 Diastolic blood pressure (mmHg) 74.9 ± 0.8 76.7 ± 1.1 73.0 ± 1.3 Pulse pressure (mmHg) $\frac{1}{7}$ 51.8 ± 1.4 53.5 ± 2.0 54.8 ± 2.3 LDL cholesterol (mg/dl) 121.7 ± 3.1 122.4 ± 4.3 121.1 ± 4.9 HDL cholesterol (mg/dl) 69.0 ± 1.7 68.3 ± 2.4 58.7 ± 2.7 LDL / HDL cholesterol $\frac{1}{7}$ 1.89 ± 0.08 1.96 ± 0.11 2.16 ± 0.11	42.9 ± 10.6	54.9 ± 7.7	55.9 ± 6.7	72.2 ± 4.8	Current/past estrogen therapy $(\%)^{\dagger}$
Waist circumference $(cm)^{\frac{1}{2}}$ 78.8 ± 1.2 80.0 ± 1.7 83.8 ± 1.9 Waist-hip ratio $\frac{1}{2}$ 0.77 ± 0.01 0.77 ± 0.01 0.80 ± 0.0 Fat compartments by EBCT $(n=104)$ $(n=49)$ $(n=40)$ Visceral fat (cm3) 59.2 ± 3.6 63.2 ± 4.9 67.2 ± 5.6 Subcutaneous fat (cm3) 155.4 ± 7.5 141.1 ± 10.3 167.8 ± 11.1 Visceral fat / subcutaneous fat 0.41 ± 0.02 0.48 ± 0.03 0.44 ± 0.02 Systolic blood pressure (mmHg) $\frac{1}{2}$ 126.7 ± 1.9 130.2 ± 2.6 127.8 ± 3.6 Diastolic blood pressure (mmHg) 74.9 ± 0.8 76.7 ± 1.1 73.0 ± 1.3 Pulse pressure (mmHg) $\frac{1}{7}$ 51.8 ± 1.4 53.5 ± 2.0 54.8 ± 2.3 LDL cholesterol (mg/dl) 121.7 ± 3.1 122.4 ± 4.3 121.1 ± 4.9 HDL cholesterol (mg/dl) 69.0 ± 1.7 68.3 ± 2.4 58.7 ± 2.7 LDL / HDL cholesterol $\frac{1}{7}$ 1.89 ± 0.08 1.96 ± 0.11 2.16 ± 0.11	26.7 ± 1.0	26.5 ± 0.8	25.6 ± 0.7	25.5 ± 0.5	Body mass index (kg/m ²)
Waist-hip ratio $\frac{1}{7}$ 0.77 ± 0.01 0.77 ± 0.01 0.80 ± 0.01 Fat compartments by EBCT $(n=104)$ $(n=49)$ $(n=40)$ Visceral fat (cm3) 59.2 ± 3.6 63.2 ± 4.9 67.2 ± 5.61 Subcutaneous fat (cm3) 155.4 ± 7.5 141.1 ± 10.3 167.8 ± 11.11 Visceral fat / subcutaneous fat 0.41 ± 0.02 0.48 ± 0.03 0.44 ± 0.02 Systolic blood pressure (mmHg) $\frac{1}{7}$ 126.7 ± 1.9 130.2 ± 2.6 127.8 ± 3.61 Diastolic blood pressure (mmHg) 74.9 ± 0.8 76.7 ± 1.1 73.0 ± 1.33 Pulse pressure (mmHg) $\frac{1}{7}$ 51.8 ± 1.4 53.5 ± 2.0 54.8 ± 2.33 LDL cholesterol (mg/dl) 121.7 ± 3.1 122.4 ± 4.3 121.1 ± 4.93 HDL cholesterol (mg/dl) 69.0 ± 1.7 68.3 ± 2.4 58.7 ± 2.77 LDL / HDL cholesterol $\frac{1}{7}$ 1.89 ± 0.08 1.96 ± 0.11 2.16 ± 0.11	82.6 ± 2.6	83.8 ± 1.9	80.0 ± 1.7	78.8 ± 1.2	Waist circumference (cm)
Fat compartments by EBCT $(n=104)$ $(n=49)$ $(n=40)$ Visceral fat (cm3) 59.2 ± 3.6 63.2 ± 4.9 67.2 ± 5.6 Subcutaneous fat (cm3) 155.4 ± 7.5 141.1 ± 10.3 167.8 ± 11.1 Visceral fat / subcutaneous fat 0.41 ± 0.02 0.48 ± 0.03 0.44 ± 0.02 Systolic blood pressure (mmHg) $\frac{1}{7}$ 126.7 ± 1.9 130.2 ± 2.6 127.8 ± 3.6 Diastolic blood pressure (mmHg) 74.9 ± 0.8 76.7 ± 1.1 73.0 ± 1.3 Pulse pressure (mmHg) $\frac{1}{7}$ 51.8 ± 1.4 53.5 ± 2.0 54.8 ± 2.3 LDL cholesterol (mg/dl) 121.7 ± 3.1 122.4 ± 4.3 121.1 ± 4.9 HDL cholesterol (mg/dl) 69.0 ± 1.7 68.3 ± 2.4 58.7 ± 2.7 LDL / HDL cholesterol $\frac{1}{7}$ 1.89 ± 0.08 1.96 ± 0.11 2.16 ± 0.11	0.79 ± 0.02	0.80 ± 0.01	0.77 ± 0.01	0.77 ± 0.01	Waist-hip ratio [‡]
Visceral fat (cm3) 59.2 ± 3.6 63.2 ± 4.9 67.2 ± 5.6 Subcutaneous fat (cm3) 155.4 ± 7.5 141.1 ± 10.3 167.8 ± 11.1 Visceral fat / subcutaneous fat 0.41 ± 0.02 0.48 ± 0.03 0.44 ± 0.02 Systolic blood pressure (mmHg) \ddagger 126.7 ± 1.9 130.2 ± 2.6 127.8 ± 3.6 Diastolic blood pressure (mmHg) 74.9 ± 0.8 76.7 ± 1.1 73.0 ± 1.3 Pulse pressure (mmHg) \ddagger 51.8 ± 1.4 53.5 ± 2.0 54.8 ± 2.3 LDL cholesterol (mg/dl) 121.7 ± 3.1 122.4 ± 4.3 121.1 ± 4.9 HDL cholesterol (mg/dl) 69.0 ± 1.7 68.3 ± 2.4 58.7 ± 2.7 LDL / HDL cholesterol \ddagger 1.89 ± 0.08 1.96 ± 0.11 2.16 ± 0.11	(n=19)	(n=40)	(n=49)	(n=104)	Fat compartments by EBCT
Subcutaneous fat (cm3) 155.4 ± 7.5 141.1 ± 10.3 167.8 ± 11.5 Visceral fat / subcutaneous fat 0.41 ± 0.02 0.48 ± 0.03 0.44 ± 0.02 Systolic blood pressure (mmHg) $\stackrel{\ddagger}{\rightarrow}$ 126.7 ± 1.9 130.2 ± 2.6 127.8 ± 3.6 Diastolic blood pressure (mmHg) 74.9 ± 0.8 76.7 ± 1.1 73.0 ± 1.3 Pulse pressure (mmHg) $\stackrel{\ddagger}{\rightarrow}$ 51.8 ± 1.4 53.5 ± 2.0 54.8 ± 2.3 LDL cholesterol (mg/dl) 121.7 ± 3.1 122.4 ± 4.3 121.1 ± 4.5 HDL cholesterol (mg/dl) 69.0 ± 1.7 68.3 ± 2.4 58.7 ± 2.7 LDL / HDL cholesterol $\stackrel{\ddagger}{\rightarrow}$ 1.89 ± 0.08 1.96 ± 0.11 2.16 ± 0.12	63.1 ± 7.9	67.2 ± 5.6	63.2 ± 4.9	59.2 ± 3.6	Visceral fat (cm3)
Visceral fat / subcutaneous fat 0.41 ± 0.02 0.48 ± 0.03 0.44 ± 0.03 Systolic blood pressure (mmHg) $\stackrel{\overrightarrow{r}}{=}$ 126.7 ± 1.9 130.2 ± 2.6 127.8 ± 3.0 Diastolic blood pressure (mmHg) 74.9 ± 0.8 76.7 ± 1.1 73.0 ± 1.3 Pulse pressure (mmHg) $\stackrel{\overrightarrow{r}}{=}$ 51.8 ± 1.4 53.5 ± 2.0 54.8 ± 2.3 LDL cholesterol (mg/dl) 121.7 ± 3.1 122.4 ± 4.3 121.1 ± 4.9 HDL cholesterol (mg/dl) 69.0 ± 1.7 68.3 ± 2.4 58.7 ± 2.7 LDL / HDL cholesterol $\stackrel{\overrightarrow{r}}{=}$ 1.89 ± 0.08 1.96 ± 0.11 2.16 ± 0.12	3 154.0 ± 16.6	167.8 ± 11.8	141.1 ± 10.3	155.4 ± 7.5	Subcutaneous fat (cm3)
Systolic blood pressure (mmHg) $\stackrel{\ddagger}{\rightarrow}$ 126.7 ± 1.9130.2 ± 2.6127.8 ± 3.4Diastolic blood pressure (mmHg)74.9 ± 0.876.7 ± 1.173.0 ± 1.3Pulse pressure (mmHg) $\stackrel{\dagger}{\rightarrow}$ 51.8 ± 1.453.5 ± 2.054.8 ± 2.3LDL cholesterol (mg/dl)121.7 ± 3.1122.4 ± 4.3121.1 ± 4.5HDL cholesterol (mg/dl)69.0 ± 1.768.3 ± 2.458.7 ± 2.7LDL / HDL cholesterol $\stackrel{\ddagger}{\leftarrow}$ 1.89 ± 0.081.96 ± 0.112.16 ± 0.11	0.42 ± 0.05	0.44 ± 0.03	0.48 ± 0.03	0.41 ± 0.02	Visceral fat / subcutaneous fat
Diastolic blood pressure (mmHg) 74.9 ± 0.8 76.7 ± 1.1 73.0 ± 1.3 Pulse pressure (mmHg) † 51.8 ± 1.4 53.5 ± 2.0 54.8 ± 2.3 LDL cholesterol (mg/dl) 121.7 ± 3.1 122.4 ± 4.3 121.1 ± 4.3 HDL cholesterol (mg/dl) 69.0 ± 1.7 68.3 ± 2.4 58.7 ± 2.7 LDL / HDL cholesterol ‡ 1.89 ± 0.08 1.96 ± 0.11 2.16 ± 0.13	141.5 ± 4.0	127.8 ± 3.0	130.2 ± 2.6	126.7 ± 1.9	Systolic blood pressure (mmHg) $\stackrel{\not\downarrow}{=}$
Pulse pressure (mmHg) ‡ 51.8 ±1.453.5 ± 2.054.8 ± 2.3LDL cholesterol (mg/dl)121.7 ± 3.1122.4 ± 4.3121.1 ± 4.9HDL cholesterol (mg/dl)69.0 ± 1.768.3 ± 2.458.7 ± 2.7LDL / HDL cholesterol ‡ 1.89 ± 0.081.96 ± 0.112.16 ± 0.13	76.9 ± 1.7	73.0 ± 1.3	76.7 ± 1.1	74.9 ± 0.8	Diastolic blood pressure (mmHg)
LDL cholesterol (mg/dl) 121.7 ± 3.1 122.4 ± 4.3 121.1 ± 4.1 HDL cholesterol (mg/dl) 69.0 ± 1.7 68.3 ± 2.4 58.7 ± 2.7 LDL / HDL cholesterol $\frac{1}{2}$ 1.89 ± 0.08 1.96 ± 0.11 2.16 ± 0.12	64.6 ± 3.1	54.8 ± 2.3	53.5 ± 2.0	51.8 ±1.4	Pulse pressure (mmHg) †
HDL cholesterol (mg/dl) 69.0 ± 1.7 68.3 ± 2.4 58.7 ± 2.7 LDL / HDL cholesterol \ddagger 1.89 ± 0.08 1.96 ± 0.11 2.16 ± 0.12	142.2 ± 6.7	121.1 ± 4.9	122.4 ± 4.3	121.7 ± 3.1	LDL cholesterol (mg/dl)
LDL / HDL cholesterol \ddagger 1.89 ± 0.08 1.96 ± 0.11 2.16 ± 0.12	66.8 ± 3.7	58.7 ± 2.7	68.3 ± 2.4	69.0 ± 1.7	HDL cholesterol (mg/dl)
	2.36 ± 0.18	2.16 ± 0.13	1.96 ± 0.11	1.89 ± 0.08	LDL / HDL cholesterol \ddagger
Fasting glucose (mmol/l) 5.34 ± 0.10 5.64 ± 0.14 5.93 ± 0.10	5.59 ± 0.21	5.93 ± 0.16	5.64 ± 0.14	5.34 ± 0.10	Fasting glucose (mmol/l)
Fasting insulin (pmol/l) 104.3 ± 7.9 115.0 ± 11.3 136.2 ± 12.3	103.0 ± 17.2	136.2 ± 12.7	115.0 ± 11.3	104.3 ± 7.9	Fasting insulin (pmol/l)

Data are mean \pm SEM or %.

EBCT, electron beam computed tomography.

Fasting glucose and fasting insulin were log-transformed.

p for trend < 0.001

```
p < 0.01
```

≠ p < 0.05.

Table 3 Odds ratio (95% CI) for increasingly severe CACS according to obesity measures in men and women

	Men		Women	
	Odds ratio (95% CI)	р	Odds ratio (95% CI)	р
BMI	1.03 (0.77–1.39)	0.84	1.01 (0.75–1.36)	0.96
Waist	1.06 (0.79–1.43)	0.69	1.10 (0.81–1.49)	0.53
Waist-hip ratio	1.21 (0.91–1.62)	0.19	1.20 (0.88–1.63)	0.26
Subcutaneous fat mass by EBCT	1.01 (0.76–1.34)	0.95	0.91 (0.68–1.22)	0.52
Visceral fat mass by EBCT	1.03 (0.78–1.36)	0.85	1.02 (0.76–1.37)	0.88
Visceral/subcutaneous fat ratio by EBCT	1.13 (0.84–1.50)	0.43	1.02 (0.76–1.37)	0.88

Based on ordinal logistic regressions; each obesity measure was considered in a separate model; all odds ratios were adjusted for age, current smoking, alcohol intake, exercise, pulse pressure, LDL cholesterol/HDL cholesterol, and fasting plasma glucose, with additional adjustment for current estrogen therapy for women only.